Lloyd Mackenzie

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

EACOM Timber Corp. engages in the manufacture and distribution of lumber and wood-based products, and the management of forest resources. It offers stud grade lumber, dimension lumber, machine-stress rated lumber, specialty lumber and engineered woods. The company was founded by Hassan Salari on April 2, 1980 and is headquartered in Montreal, Canada.

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada.

Notable Labs, Inc. provides personalized testing services for cancer patients. Its testing prioritizes combinations of FDA-approved treatments that can be prescribed by a doctor without a clinical trial. The company was founded by Peter Quinzio and Matthew De Silva in 2013 and is headquartered in Foster City, CA.

Symvivo Corp. is a Canadian clinical-stage biotechnology company that specializes in advancing therapeutics in the area of oral DNA vaccines, oncology, immunology, and gene replacement. The private company's Bactrl platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient's own cells to produce therapeutic proteins. Symvivo is headquartered in Burnaby, Canada. The company was founded by Alexander Graves, who has been the CEO since incorporation.